Clinical relevance of fatigue as a residual symptom in major depressive disorder

Depression and Anxiety

Volumn 31, Issue 3, 2014, Pages 250-257

  Fava, Maurizio ^a   Ball, Susan ^b,c   Nelson, J Craig ^d   Sparks, Jondavid ^b   Konechnik, Thomas ^b   Classi, Peter ^b   Dube, Sanjay ^c,e   Thase, Michael E ^f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

fatigue; functioning; major depressive disorder; remission; residual symptoms

Indexed keywords

AMFEBUTAMONE; DESIPRAMINE; LOFEPRAMINE; MAPROTILINE; METHYLPHENIDATE; MODAFINIL; NORTRIPTYLINE; PLACEBO; REBOXETINE;

ANXIETY; CLINICAL TRIAL; DEPRESSION; FATIGUE; HUMAN; MAJOR DEPRESSION; MONITORING; PREVALENCE; PRIORITY JOURNAL; RECOGNITION; REMISSION; REVIEW; SLEEP DISORDER; SOCIAL PSYCHOLOGY; TREATMENT DURATION; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; METABOLISM;

DEPRESSIVE DISORDER, MAJOR; FATIGUE; HUMANS;

EID: 84895929640     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22199     Document Type: Review

References (63)

1. Trivedi MH, Rush AJ, Wisniewski SR, et al. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40.
2. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-1917.
3. Kennedy N, Paykel ES,. Residual symptoms at remission from depression: impact on long-term outcome. J Affect Disord 2004; 80: 135-144.
4. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000; 157: 1501-1504.
5. Paykel ES, Ramana, R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995; 25: 1171-1180.
6. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998; 50: 97-108.
7. Bockting CL, Spinhoven P, Koeter MW, et al.; Depression Evaluation Longitudinal Therapy Assessment Study Group. Prediction of recurrence in recurrent depression and the influence of consecutive episodes on vulnerability for depression: a 2-year prospective study. J Clin Psychiatry 2006; 67: 747-755.
8. Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2010; 40: 41-50.
9. Miller IW, Keitner GI, Schatzberg AF, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998; 59: 608-619.
10. Papakostas GI, Petersen T, Denninger JW, et al. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol 2004; 24: 507-511.
11. Trivedi MH, Corey-Lisle PK, Guo Z, et al. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. Int Clin Psychopharmacol 2009; 24: 133-138.
12. Tranter R, O'Donovan C, Chandarana P, Kennedy S,. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 2002; 27: 241-247.
13. Judd LL, Schettler PJ, Akiskal HS,. The prevalence, clinical relevance, and public health significance of subthreshold depressions. Psychiatr Clin North Am 2002; 25: 685-698.
14. Mintz J, Mintz LI, Arruda MJ, Hwang SS,. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992; 49: 761-768. Erratum in: Arch Gen Psychiatry 1993;50:241.
15. Swindle R, Kroenke K, Braun L,. Energy and improved workplace productivity in depression. In:, Farquhar I, Sorkin A, Summers K, editors. Investing in Health: The Social and Economic Benefits of Health Care Innovation. Bradford: Emerald Group Publishing; 2001: 323-341.
16. Knoth RL, Bolge SC, Kim E, Tran QV,. Effect of inadequate response to treatment in patients with depression. Am J Manag Care 2010; 16: e188-e196.
17. Conradi HJ, Ormel J, de Jonge P,. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med 2010; 8: 1-10.
18. Portenoy RK, Itri LM,. Cancer-related fatigue: guidelines for evaluation and management. Oncologist 1999; 4: 1-10.
19. Pae CU, Lim HK, Han C, et al. Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion. Expert Rev Neurother 2007; 7: 1251-1263.
20. Pedrelli P, Baer L, Losifescu DV, Fava M,. Relationship between residual symptoms of depression and self-reported cognitive impairment. CNS Spectr 2010; 15: 46-51.
21. Shen J, Barbera J, Shapiro CM,. Distinguishing sleepiness and fatigue: focus on definition and measurement. Sleep Med Rev 2006; 10: 63-76.
22. Ferentinos PP, Kontaxakis VP, Havaki-Kontaxaki BJ, et al. The measurement of fatigue in depression. Psychopathology 2007; 40: 133-134.
23. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD,. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-1123.
24. FDA. Guidance for Industry-Patient-Reported Outcome Measure: Use in Medical Product Development to Support Labeling Claims. 2009.
25. Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res 1993; 37: 147-153.
26. Ferentinos P, Kontaxakis V, Havaki-Kontaxaki B, et al. The Fatigue Questionnaire: standardization in patients with major depression. Psychiatry Res 2010; 177: 114-119.
27. Matza, LS, Phillips, GA, Revicki, DA, et al. Development and validation of a patient-report measure of fatigue associated with depression. J Affect Disord 2011; 134: 294-303.
28. Matza LS, Wyrwich KW, Phillips GA, Murray LT, Malley KG, Revicki DA,. The Fatigue Associated with Depression Scale: responsiveness and responder definition. Qual Life Res 2013; 22 (2): 351-360. doi: 10.1007/s11136-012-0142-6. [Epub] March 9, 2012.
29. Fava M, Iosifescu DV, Pedrelli P, Baer L,. Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire. Psychother Psychosom 2009; 78: 91-97.
30. Hybels CE,., Steffems DC, McQuoid DR, Krishnan KR,. Residual symptoms in older patients treated for major depression. Int J Geriatr Psychiatry 2005; 20: 1196-1202.
31. McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol 2011; 31: 180-186.
32. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999; 60: 221-225.
33. Fava M, Graves LM, Benazzi F, et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry 2006; 67: 1754-1759.
34. Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2010; 40: 41-50.
35. Greco T, Eckert G, Kroenke K,. The outcomes of physical symptoms with treatment of depression. J Gen Intern Med 2004; 19: 813-818.
36. Fava M, Hoog SL, Judge RA, et al. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol 2002; 22: 137-147.
37. Stahl SM, Zhang L, Damatarca C, Grady M,. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry 2003; 64 (Suppl 14): 6-17.
38. Demyttenaere K, De Fruyt J, Stahl SM,. The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol 2005; 8: 93-105.
39. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990; 47 (5): 411-418.
40. Delgado PL, Miller HL, Salomon RM, et al. Monoamines and the mechanism of antidepressant action: effects of catecholoamine on mood of patients treated with antidepressants. Psychopharmacol Bull 1993; 29: 389-396.
41. Berman RM, Narasimhan M, Miller HL, et al. Transient depressive relapse induced by catecholamine depletion: potential phenotypic vulnerability marker? Arch Gen Psychiatry 1999; 56: 395-403.
42. Nelson JC, Mazure C, Quinlan DM, Jatlow PI,. Drug-responsive symptoms in melancholia. Arch Gen Psychiatry 1984; 41: 663-668.
43. Nelson JC, Portera L, Leon AC,. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor? Biol Psychiatry 2005; 57: 1535-1542.
44. Anisman H, Merali Z, Poulter MO, Hayley S,. Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Des 2005; 11: 963-972.
45. Simon NM, McNamara K, Chow CW, et al. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol 2008; 18: 230-233.
46. Irwin MR, Miller AH,. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 2007; 21: 374-383.
47. Keller MB,. Remission versus response: the new gold standard of antidepressant care. J Clin Psychiatry 2004; 65 (Suppl 4): 53-59.
48. Daly EJ, Trivedi MH, Fava M, et al. The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study. J Clin Psychopharmacol 2011; 31: 31-38.
49. Ball SG, Dellva MA, D'Souza D, Marangell L, et al. A double-blind, placebo-controlled study of augmentation with LY2216684 for major depressive disorder patients who are partial responders to selective serotonin reuptake inhibitors. Int J Psych Clin Pract 2010; 14 (Suppl 1): 19.
50. Lam RW, Michalak EE, Bond DJ, Tam EM, Axler A, Yatham LN,. Which depressive symptoms and medication side effects are perceived by patients as interfering most with occupational functioning? Depress Res Treat 2012. Article ID: 630206. doi: 10.1155/2012/630206, http://www.hindawi.com/journals/drt/2012/ 630206/.
51. Lam RW, Malhi GS, McIntyre RS, et al. Fatigue and occupational functioning in major depressive disorder. Aust NZ J Psychiatry 2013 [Epub ahead of print], doi. 10.1177/0004867413488222.
52. Kroenke K, Spitzer RL, Williams JB,. The PHQ-9: validity of a brief depression severity measure. J Intern Med 2001; 16 (9): 606-613.
53. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), Clinician Rating (QIDS-C) and Self-Report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54 (5): 573-583.
54. STAR*D Sequential Treatment Alternatives to Relieve Depression Assessment Forms. Available at: http://www.edc. gsph.pitt.edu/stard/public/ assessment-forms.html
55. Fava M, Rush AJ, Thase ME, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005; 7: 106-113.
56. Papakostas GI, Nutt DJ, Hallett LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry 2006; 60: 1350-1355.
57. Nelson JC,. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry 1999; 46: 1301-1308.
58. Papakostas GI, Peterson, TJ, Burns AM, Fava M,. Adjunctive atomoxetine for residual fatigue in major depressive disorder. J Psychiatr Res 2006; 40: 370-373.
59. Michelson D, Adler LA, Amersterdam JD, et al. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo controlled study. J Clin Psychiatry 2007; 68: 582-587.
60. Jones CB, Williams R, Tookman A, King M,. Psychostimulants and depression. Cochrane Libr 2008; 2.
61. DeBattista C, Doghramji K, Menza MA, et al., Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind placebo-controlled study. J Clin Psychiatry 2003; 64: 1057-1064.
62. Fava M, Thase ME, DeBattista C,. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005; 66: 85-93.
63. Fava M, Thase ME, DeBattista C, et al. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry 2007; 19: 153-159.